All In Biotech

Drug Trial Radar · NCT05534529

Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age

A Phase 1, Multicentre, Open-Label Study to Evaluate the PK, Safety, and Tolerability of a Single IV Dose of Rezafungin in Paediatric Subjects, Receiving Systemic Antifungals as Prophylaxis for IFI or to Treat a Suspected or Confirmed FI

Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

32

Actual

Start

Sep 13, 2023

Primary completion

May 23, 2024

Study completion Oct 14, 2024

Sponsor

Lead sponsor
Mundipharma Research LimitedIndustry
Sponsor type
Industry
First posted
Sep 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to learn what levels of rezafungin were in the blood after dosing and how safe it was, in children and adolescents below 18 years old who were already receiving treatment for a fungal infection, a suspected fungal infection or at risk of fungal infection. The main question the researchers wanted to answer in this trial was: • What were the levels of rezafungin in the blood after the participants were dosed? The researchers also wanted to know what medical problems happened during this trial. The participants in this trial received one dose of rezafungin on day 1 through a needle into a vein, called an intravenous (IV) infusion. The dose of rezafungin was measured in milligrams (mg) and given to the participants according to their body weight in kilograms (mg/kg). The doctors checked the participants' health and asked questions about what medications they were taking and took blood samples to check the levels of rezafungin in the participants' blood. After receiving the treatment at day 30, the doctors checked the participants' health. This was an "open-label" trial. This means each participant knew what they were receiving, and the doctors and trial staff also knew.

Conditions

  • Invasive Fungal Infections

Interventions

  • Rezafungin AcetateDrug

    This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of RezafunginTime frame: At end-of-infusion ± 15 minutes, then between 3 and 4 hours after start of infusion, between 6 and 8 hours after start of infusion, at 48 hours (± 4 hours) after start of infusion, and at 168 hours (± 12 hours) after start of infusion
  2. Time at which the Cmax of Rezafungin Was Observed (Tmax)Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion
  3. Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of RezafunginTime frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion
  4. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of RezafunginTime frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion
  5. Total Clearance (CL) of RezafunginTime frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion
  6. Volume of Distribution of Rezafungin at Steady-state (Vss)Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion
  7. Apparent Volume of Distribution of Rezafungin During the Terminal Phase (Vz)Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion
  8. Terminal Elimination Half-life of Rezafungin (t1/2)Time frame: End of infusion and 3-4, 6-8, 48, and 168 hours after start of infusion

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Universitätsklinikum Essen Zentrum für Kinder- und Jugendmedizin

    Essen, Germany

  • Universitätsklinikum Frankfurt, Goethe Universität Klinik für Kinder- und Jugendmedizin

    Frankfurt, Germany

  • Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin

    Münster, Germany

  • Hospital Universitario de Burgos

    Burgos, Spain

  • Hospital Universitario 12 de Octubre.

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom

  • Saint Mary's Hospital, Imperial College Healthcare NHS Trust

    London, United Kingdom

  • St. George's University Hospitals, NHS Foundation Trust

    London, United Kingdom

  • Southampton General Hospital, University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.